| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
COPN Stock Overview
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide.
Cosmo Pharmaceuticals N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF47.50 |
| 52 Week High | CHF76.50 |
| 52 Week Low | CHF42.30 |
| Beta | 1.01 |
| 1 Month Change | -8.48% |
| 3 Month Change | -2.16% |
| 1 Year Change | -34.57% |
| 3 Year Change | -39.41% |
| 5 Year Change | -68.33% |
| Change since IPO | 113.00% |
Recent News & Updates
Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals
Cosmo Pharmaceuticals N.V. ( VTX:COPN ) announced strong profits, but the stock was stagnant. We did some digging, and...
Shareholder Returns
| COPN | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | 7.3% | 4.1% | 4.1% |
| 1Y | -34.6% | 1.1% | -12.8% |
Return vs Industry: COPN underperformed the Swiss Pharmaceuticals industry which returned -0.7% over the past year.
Return vs Market: COPN underperformed the Swiss Market which returned -15% over the past year.
Price Volatility
| COPN volatility | |
|---|---|
| COPN Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in CH Market | 7.6% |
| 10% least volatile stocks in CH Market | 2.2% |
Stable Share Price: COPN is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: COPN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 292 | Alessandro Della Cha | https://www.cosmopharma.com |
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler’s diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris.
Cosmo Pharmaceuticals N.V. Fundamentals Summary
| COPN fundamental statistics | |
|---|---|
| Market Cap | CHF778.22m |
| Earnings (TTM) | CHF34.45m |
| Revenue (TTM) | CHF76.32m |
22.6x
P/E Ratio10.2x
P/S RatioIs COPN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COPN income statement (TTM) | |
|---|---|
| Revenue | €78.17m |
| Cost of Revenue | €36.40m |
| Gross Profit | €41.76m |
| Other Expenses | €6.48m |
| Earnings | €35.28m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.15 |
| Gross Margin | 53.43% |
| Net Profit Margin | 45.14% |
| Debt/Equity Ratio | 36.1% |
How did COPN perform over the long term?
See historical performance and comparison